Search - Browse Site

Investment Alert Invest in the Future of Digital Assets and Biotech Innovation Coeptis Therapeutics Holdings Inc. (NASDAQ: COEP) + Z Squared Merger | Q3 2025 A bold pivot. A strategic merger. A dual-industry powerhouse. Coeptis Therapeutics Holdings Inc. is on the verge of a game-changing transformation—merging with Z Squared Inc., a leading Dogecoin mining company, to create one of the largest publicly traded digital asset mining firms in the world. With the merger slated to close in Q3 2025, pending regulatory approvals, investors have a rare opportunity to get in early on a high-growth, diversified enterprise.. Experience the power of growth Business Overview: From Cell Therapy to Crypto Mining NASDAQ: COEP has long been a pioneer in oncology-focused cell therapy platforms, developing technologies like SNAP-CAR and GEAR-NK for cancer treatment. But with the upcoming merger, Coeptis will spin out its biopharma operations and rebrand as Z Squared Inc., shifting its core focus to digital asset mining—primarily Dogecoin (DOGE). Key Highlights: Coeptis will acquire 9,000 U.S.-based Dogecoin mining machines at closing Z Squared becomes a wholly-owned subsidiary of Coeptis Biopharma division to operate independently post-merger New leadership team from Z Squared with deep expertise in digital assets This strategic realignment positions Coeptis to capitalize on two high-growth sectors: biotech innovation and blockchain infrastructure. Is it time to analyze your investments? Market Analysis: Riding the Wave of Crypto Expansion Dogecoin, once a meme, now commands a market cap exceeding $20 billion. Its proof-of-work (PoW) mechanism rewards miners with DOGE for validating transactions, creating a lucrative revenue stream for mining operations. Why This Market Matters: Growing adoption of DOGE for payments and smart contracts Increasing institutional interest in crypto mining infrastructure Regulatory clarity improving in key markets With 9,000 mining machines and a focus on U.S.-based operations, Z Squared is poised to become a dominant force in the Dogecoin ecosystem Competitive Analysis: A Unique Dual-Industry Advantage While most crypto mining companies focus solely on digital assets, Coeptis offers a differentiated value proposition: Feature "COEP"/Z Squared Traditional Crypto Miners Biotech Firms Dogecoin Mining Scale ✅ 9,000 machines    Limited exposure ❌  None Nasdaq Listing ✅  Yes ✅  Some ✅  Yes Biotech Legacy ✅  Oncology platforms ❌  None ✅  Core focus Diversification ✅  Dual-sector ❌  Single-sector ❌  Single-sector Financial Projections: Unlocking Multi-Billion Dollar Potential While full post-merger financials are pending SEC filings, early indicators suggest strong upside: Current COEP Market Cap:  ~$27.7M DOGE Mining Revenue Potential:  Estimated $15M–$25M annually from 9,000 machines (based on current DOGE prices and mining yields) Biotech IP Value: Coeptis retains rights to proprietary cell therapy platforms, which may be monetized or spun off With crypto prices rebounding and biotech assets maturing, the combined entity offers asymmetric upside for early investors Why Invest Now? Ground-floor entry into a high-capacity Dogecoin mining operation  Exposure to biotech IP with potential licensing or acquisition upside  Nasdaq-listed liquidity and transparency  Experienced leadership from Group 10 Capital and Minting Dome Inc. This isn’t just a pivot—it’s a launchpad. The merger of Coeptis and Z Squared is a rare convergence of innovation, infrastructure, and investor opportunity. Price on the Move Here’s the current stock snapshot as of Sept 5, 2025 for Coeptis Therapeutics Holdings Inc. (NASDAQ: COEP) References Coeptis Therapeutics Official Website Coeptis-Z Squared Merger Announcement – Coeptis Investors Page   Merger Press Release – GlobeNewswire   COEP Stock Overview – Nasdaq Explore more at investors.coeptistx.com and join the future of biotech, AI, and digital assets. DISCLAIMER Vanderbiltreport.com is owned and operated by AB Holdings, a US-based corporation. We have received compensation of up to $100,000  regarding the profiling of Coeptis Therapeutics Holdings Inc.  (NASDAQ: COEP).   )  starting on Sept 1, 2025. It is important to note that we do not own any shares in COEP: NASDAQ . This page includes forward-looking statements subject to substantial risks and uncertainties. Actual outcomes may differ due to clinical trial results, regulatory decisions, financing needs, and execution. Investors should consult SEC filings before making decisions.

Stemteck Corporation (QTCQB: STEK),   is pioneering a new frontier in health and wellness through stem cell nutrition and regenerative science. With a proven track record, innovative product lines, and expansion into high-growth markets, Stemtech offers a unique opportunity for investors seeking exposure to the booming wellness and anti-aging sectors. Stemtech Corporation is a stemceutical company  specializing in science-based nutritional supplements  that support the body’s natural stem cell functions. Founded in 2005 and publicly traded since 2021, Stemtech develops and distributes products that promote cellular renewal, vitality, and longevity. Key Products: StemRelease3® – Enhances stem cell release and circulation StemFlo® – Supports blood flow and stem cell migration Rapid Renew® Stem Cell Peptide Cream  – Anti-aging skincare OraStem® – All-natural oral care StemPets™ – Nutraceuticals for pet wellness (launching 2025) Distribution Model:  Stemtech operates through a direct sales network  of Independent Business Partners across the Americas, Asia, and Latin America, creating scalable growth and recurring revenue streams. The global wellness industry is booming, and Stemtech is strategically positioned in two of its fastest-growing segments: Market Segment 2025 Est. Value CAGR (2023–2028) Stemtech’s Role Stem Cell Nutrition $15B+ 10.2% Core product line Anti-Aging Skincare $83B+ 7.8% Rapid Renew® Pet Health & Wellness $303B 6.1% StemPets™ launch Stemtech’s expansion into the pet wellness market  and continued innovation in anti-aging solutions position it to capture significant market share. Stemtech stands apart from traditional supplement companies with its stem cell-centric approach  and proprietary formulas. Feature Stemtech Traditional Wellness Brands Stem Cell Nutrition Focus ✅ Yes ❌ No Proprietary Peptide Skincare ✅ Yes ❌ Limited Direct Sales Distribution ✅ Scalable ❌ Retail-dependent Pet Nutraceuticals Expansion ✅ 2025 Launch ❌ Few offerings Stemtech’s first-mover advantage in stemceuticals and its multi-channel distribution  model provide a durable competitive moat. Stemteck Corporation (QTCQB: STEK) Despite current undervaluation, Stemtech is poised for a turnaround and long-term growth. Recent Financials: Market Cap: ~$2.1M Revenue (TTM): $5.05M EPS: -$0.03 (reflecting reinvestment in growth) Growth Catalysts: Strategic merger with Viago and Seacret Direct Launch of StemPets™ in 2025 Expansion into Asia and Latin America New leadership and marketing initiatives Stemteck Corporation (QTCQB: STEK)   Trading near 52-week low ($0.0140–$0.0650) High upside potential with low entry cost Positioned in high-growth wellness verticals Proven leadership and product innovation Join the Cellular Wellness Revolution Stemtech Corporation is more than a supplement company—it's a movement toward regenerative health, longevity, and vitality. With a robust product pipeline, expanding global footprint, and strategic vision, Stemtech offers investors a rare opportunity to be part of the next wave in wellness innovation Learn more on Stemtech’s official site   View STEK on Yahoo Finance References Stemtech Official Website Yahoo Finance – STEK Overview ADVFN – Stemtech Financials   Stockhouse – $7M Investment Announcement DISCLAIMER Vanderbiltreport.com  is owned and operated by AB Holdings, a US-based corporation. We have not received any compensation regarding the profiling of Stemteck Corporation.   (OTCQB: STEK).  It is important to note that we do not own any shares in SYEK: OTCQB . This page includes forward-looking statements subject to substantial risks and uncertainties. Actual outcomes may differ due to clinical trial results, regulatory decisions, financing needs, and execution. Investors should consult SEC filings before making decisions.

Business Overview: A Strategic Gold Explorer with Scale   Provenance Gold Corp (CSE: PAU | OTCQB: PVGDF) is laser-focused on unlocking value from its portfolio of gold assets in North America. Its flagship Eldorado Project  in Oregon is a district-scale property with historical estimates suggesting nearly 2 million ounces of gold —yet it remains largely under the radar. Why This Matters: Massive upside potential : Historical drilling (over 22,000 meters) confirms broad, shallow mineralization, ideal for open-pit development. Low-cost extraction : Metallurgical testing supports heap leaching and gravity recovery—resulting in lower capital expenditures (capex) and faster scalability. Aggressive exploration strategy : Recent RC drilling is expanding known zones and targeting high-grade feeder systems. This is not a speculative land package—it’s a data-rich, drill-confirmed gold system with near-term resource definition potential. It is a good day to buy Gold -  Provenance Gold Corp (CSE: PAU | OTCQB: PVGDF) Market Analysis: Gold’s Resurgence and Provenance’s Leverage Gold is once again in the spotlight. With inflationary pressures, geopolitical instability, and central bank accumulation driving demand, investors are turning to gold—and junior explorers are the most leveraged way to play the trend. Strategic Positioning: Gold prices near all-time highs : Provenance offers asymmetric upside as even modest resource growth can dramatically re-rate its valuation. Safe jurisdiction advantage : Operating in Oregon and Nevada, Provenance avoids the political risk plaguing many global peers. Investor sentiment shift : Capital is flowing back into exploration-stage companies, especially those with credible assets and strong management. Provenance is perfectly positioned to ride this wave, offering exposure to gold with the torque of a junior explorer and the credibility of a seasoned team. Competitive Analysis: Provenance vs. the Field In a crowded junior gold space, Provenance Gold differentiates itself with real assets, real data, and real progress. Feature Provenance Gold Corp Typical Junior Explorer Historical Resource Estimate ~1.98M oz (non-compliant) Often speculative or absent Drill Data 22,000+ meters Limited or early-stage Metallurgical Testing Heap leach & gravity viable Rare at early stage Jurisdiction Oregon & Nevada Mixed, often high-risk Management Track Record Proven geological leadership Often promotional Provenance isn’t chasing dreams—it’s executing a strategy. With a clear roadmap and tangible milestones, it offers investors a de-risked entry into a high-potential gold system. Financial Projections & Valuation Potential: Undervalued and Catalyst-Rich   Provenance Gold  Corp (CSE: PAU | OTCQB: PVGDF) Despite its progress, Provenance trades at a steep discount to its peers—creating a window of opportunity for early investors. Investment Case: Valuation arbitrage : Provenance trades at a fraction of its in-ground potential, offering significant re-rating potential as drilling continues. Multiple catalysts ahead : Drill results, resource updates, and permitting progress could unlock rapid value. Strong insider alignment : Management and insiders hold meaningful stakes, signaling confidence and long-term commitment. For investors seeking growth, Provenance offers a rare combination: low entry price, high asset quality, and near-term news flow. Conclusion: A Ground-Floor Opportunity in a Rising Gold Market Provenance Gold  Corp (CSE: PAU | OTCQB: PVGDF) is not just another junior—it’s a company with scale, strategy, and momentum. As gold continues to shine, Provenance offers investors a front-row seat to potential discovery, resource growth, and value creation. This is the kind of opportunity that smart capital seeks: early-stage access to a credible gold system, backed by data, driven by results, and priced for upside. If you're looking to position yourself ahead of the curve, Provenance Gold deserves your attention—before the rest of the market catches on. References Provenance Gold Corp – Official Website Real-time Stock Data – Bing Finance ADVFN – PAU Stock Quote & Metrics Latest Drill Results – Provenance Gold News Release PVGDF Stock Overview – StockAnalysis.com DISCLAIMER Vanderbiltreport.com is owned and operated by AB Holdings, a US-based corporation. We have received compensation of up to $100,000  regarding the profiling of Provenance Gold Corp (CSE: PAU | OTCQB: PVGDF) )  starting on Sept 1, 2025. It is important to note that we do not own any shares in Provenance Gold Corp (CSE: PAU | OTCQB: PVGDF). This page includes forward-looking statements subject to substantial risks and uncertainties. Actual outcomes may differ due to clinical trial results, regulatory decisions, financing needs, and execution. Investors should consult SEC filings before making decisions.

Transforming Oncology & Vaccine Therapeutics Medicus Pharma Ltd. (NASDAQ: MDCX) is a clinical-stage, multi-strategy holding company dedicated to investing in innovative life sciences and biotechnology firms through FDA-approved clinical trials. The Company specializes in identifying, acquiring, and advancing relatively de-risked clinical-stage assets throughout their development and commercialization phases. To enhance its drug development pipeline, Medicus Pharma is actively pursuing acquisitions and strategic partnerships. Through its subsidiary, SkinJect, Inc., the Company is focused on developing a cutting-edge drug delivery system utilizing novel dissolvable microneedle arrays for the treatment of specific skin cancers. SkinJect represents a minimally invasive approach to treating common forms of non-melanoma skin cancer, including basal cell carcinoma and squamous cell carcinoma. Vanderbiltreport Alert - This stock is a Sleeping Giant Investment Highlights Diversified Clinical Pipeline -  SkinJect / D-MNA Microneedle Patch – Phase 2 trial for basal cell carcinoma underway; FDA engagement progressing. -  Teverelix (via Antev Acquisition) – GnRH antagonist for prostate cancer & acute urinary retention, addressing a $6B+ market opportunity. -  mRNA + Microneedle Collaboration (HelixNano) –  Thermostable vaccines for infectious diseases. Strong Financial Position -  $9.7M cash on hand (Q2 2025). -  Recently raised $4.2M via Reg A + $7.0M public offering. -  Acquisition structured with milestone-based payments, limiting dilution. Leadership & Execution -  Proven biotech veterans onboard, including Patrick J. Mahaffy (Clovis Oncology, Pharmion). -  Strategic hires and Deloitte engaged to explore out-licensing opportunities.     Call your Broker now! Market Opportunity -  Skin Cancer (Basal Cell Carcinoma): >5M new U.S. cases annually, ~$2B addressable market. -  Prostate Cancer & Urology: ~$6B+ combined global opportunity. -  Global Vaccines: Expanding market with delivery & distribution advantages.    Why Invest Now? ✔ Late-stage assets with clear regulatory milestones. ✔ Multiple shots on goal in oncology, urology, and vaccines. ✔ Strengthened balance sheet and capital-efficient acquisitions. ✔ Experienced team with track record of building and scaling biotechs.      Join us in building wealth, one investment at a time Contact Investor Relations info@medicuspharma.com www.medicuspharma.com DISCLAIMER Snapmediagroup.net  and Vanderbiltreport.com  are owned and operated by SMG a US-based corporation. We have received compensation of up to $100,000  regarding the profiling of Medicus Pharma Ltd.   (Nasdaq: MDCX)  starting on Sept 5, 2025. It is important to note that we do not own any shares in MDCX: NASDAQ .

A Bold Hybrid of Biotech Innovation and Emerging Technologies Coeptis Therapeutics is redefining the future of healthcare and digital infrastructure. With a diversified pipeline of cell therapies, strategic expansion into AI and automation, and a transformative merger into crypto mining, Coeptis offers investors a rare opportunity to participate in multiple high-growth sectors—all under one Nasdaq-listed company. Business Overview Experience the power of growth Coeptis Therapeutics Holdings Inc., headquartered in Wexford, Pennsylvania, is a biopharmaceutical and technology company focused on developing transformative therapies for cancer, autoimmune, and infectious diseases. Its portfolio includes: DVX201 : A clinical-stage, unmodified natural killer (NK) cell therapy targeting solid tumors and hematologic malignancies. SNAP-CAR : A universal CAR T platform enabling multi-antigen targeting through antibody co-administration. GEAR-NK (CD38) : A novel cell therapy and companion diagnostic platform for CD38-expressing cancers such as multiple myeloma and leukemia. In parallel, Coeptis has acquired AI-powered marketing and robotic process automation tools from NexGenAI Solutions Group, expanding its footprint into scalable tech solutions. Is it time to analyze your investments? Market Analysis The global cell therapy market is projected to surpass $45 billion by 2030 , driven by rising cancer rates and demand for personalized medicine. Coeptis is positioned to capitalize on this growth with differentiated platforms and strategic partnerships. Meanwhile, the company’s merger with Z Squared Inc. , a Dogecoin mining firm, will create the largest publicly traded Dogecoin-focused mining company. This move offers investors exposure to the booming digital asset market, while spinning out Coeptis’ biopharma assets into a separate entity. Key Market Drivers: Sector Growth Catalyst Coeptis Advantage Cell Therapy Personalized oncology & rare disease demand Diversified pipeline with clinical assets AI & Automation Enterprise efficiency & cost reduction NexGenAI acquisition Crypto Mining Decentralized finance & blockchain expansion Z Squared merger Competitive Analysis Coeptis differentiates itself through: Multi-modal pipeline : Targeting both hematologic and solid tumors, respiratory diseases, and neurodegenerative conditions. Strategic licensing : Collaborations with Deverra Therapeutics, University of Pittsburgh, and VyGen-Bio provide access to cutting-edge platforms. Lean operations : With just five full-time employees, Coeptis maintains agility and cost-efficiency. Nasdaq listing : Offers liquidity, transparency, and institutional access. Compared to single-asset biotech firms, Coeptis offers a diversified, de-risked portfolio with upside across multiple verticals.   Financial Projections While Coeptis is pre-revenue in biotech, its financial outlook is compelling: Analyst Price Targets : EF Hutton and JonesTrading forecast COEP shares between $60 and $200 , representing potential upside of over 1,400% . EPS Trajectory : Projected improvement from –$5.10 in 2024  to –$0.17 by 2026 , signaling a path toward breakeven. Market Cap : Currently valued at ~$57 million, offering a low entry point for investors seeking asymmetric returns. Investment Alert Why Invest in COEP? Diversified Growth Engines : Exposure to biotech, AI, and crypto—three of the most disruptive sectors of the next decade. Clinical Momentum : Multiple therapies advancing toward human trials with strong IP protection. Strategic Vision : Bold moves like the Z Squared merger and AI acquisitions show a commitment to long-term value creation. Undervalued Potential : With analyst targets far above current price, COEP offers significant upside for early investors. Price on the Move Here’s the current stock snapshot as of Sept 5, 2025 for Coeptis Therapeutics Holdings Inc. (NASDAQ: COEP) References Coeptis Therapeutics – Investor Relations Corporate Overview – Coeptis Therapeutics Merger Announcement – Coeptis & Z Squared Stock Forecast – StockAnalysis.com MarketBeat – COEP Stock Analysis Yahoo Finance – COEP Overview Explore more at investors.coeptistx.com and join the future of biotech, AI, and digital assets. DISCLAIMER Snapmediagroup.net and Vanderbiltreport.com are owned and operated by SMG a US-based corporation. We have received compensation of up to $100,000  regarding the profiling of Coeptis Therapeutics Holdings Inc.  (NASDAQ: COEP).   )  starting on Sept 1, 2025. It is important to note that we do not own any shares in MDCX: NASDAQ . This page includes forward-looking statements subject to substantial risks and uncertainties. Actual outcomes may differ due to clinical trial results, regulatory decisions, financing needs, and execution. Investors should consult SEC filings before making decisions.

AI-Powered Athletic Performance & Injury Prevention No Wearables, No Sensors, No Limits. Welcome to Atlas Athlete by MyMedicalHub – the cutting-edge platform that’s revolutionizing how athletes assess, understand, and improve their musculoskeletal health. What Is Atlas Athlete? Atlas Athlete is an AI-powered platform that delivers a comprehensive musculoskeletal health assessment in under 45 minutes—no sensors, wearables, or specialized gear required. It’s perfect for athletes on the go and the professionals who support them. Built for Accuracy. Designed for Access. Accessible Anywhere: Use any device with a camera AI-Powered Motion Analysis:  Clinically validated, real-time feedback Fast & Non-Invasive:  Full assessment in under 45 minutes Science-Backed: Developed in collaboration with health and sports performance experts Why Athletes & Teams Choose Atlas Athlete Quick, Actionable Results Personalized Training & Recovery Recommendations Injury Risk Detection Before It’s Too Late Mobile, Accessible & Scalable for Individuals and Teams Cloud-Based for Seamless Integration & Tracking Training Smarter   For Sports Medicine Professionals Get fast, objective movement assessments to help guide treatment, track recovery, and optimize athletic readiness—all without wearables or extra equipment.   Why Athlete’s Use Atlas Athlete Know Your Body: Understand your movement patterns and potential imbalances Prevent Injuries: Catch red flags before they turn into setbacks Track Progress: Use data to improve strength, mobility, and performance No Equipment Needed: Run your assessment between classes, practices, or on the road Why Sports Medicine Professionals Trust It Objective, Repeatable Data:  Support evaluations, rehab, and return-to-play decisions Baseline & Comparative Reporting:  Monitor progress over time Scalable for Teams & Clinics:  Assess individuals or entire rosters quickly Documented Outcomes: Useful for compliance, reporting, and parent/staff communication How It Works Launch from Any Device:  Phone, tablet, or computer camera Follow Guided Movements:  Our AI captures biomechanics in real time Get a Full Report: Instant insights into mobility, stability, and injury risk Trusted by Athletic Trainers, PTs, Coaches & Schools Nationwide Whether you're working with a single athlete or an entire program, Atlas Athlete brings cutting-edge motion assessment  to your fingertips—efficient, accurate, and cost-effective.   Exclusive Offer: Only $59.99 Take advantage of this limited-time opportunity to enhance your experience at an exceptional value. For just $59.99, you can access our premium services and enjoy the benefits that come with them. Don’t miss out on this chance to elevate your experience—act now! Or Call Us: 844 680 0052 Ready to Elevate Your Health & Performance? For Athletes: Take control of your health and performance—anywhere, anytime. Start Your Assessment For Sports Medicine Professionals: Save time, improve outcomes, and support athletes with smarter data. Request a Demo See How It Works Atlas Athlete by MyMedicalHub Smarter Assessments. Stronger Athletes. Safer Play. Email - support@mymedicalhub.com Phone - 844.680.0052

Company Analysis 1. Company Overview Brookmount Explorations, Inc. (BMXI) is a gold production and exploration company incorporated in Nevada. It owns and operates gold mining assets in: ●     Indonesia  (2 producing sites in Sulawesi) ●     North America  (Moosehorn Project – Yukon, and McArthur Creek – Alaska) Strategy : Expand high-grade gold production, increase throughput, and consolidate ownership. Recent Development : As of December 2024, the company assumed full operational control of its Indonesian joint ventures. 2. Risk Summary Operational Risks ●     High dependency on Indonesian production (single-region concentration) ●     Exposure to natural, regulatory, and geopolitical risks in emerging markets ●     Logistical and environmental complexity in remote rainforest mining Financial Risks ●     Heavy reliance on convertible debt  financing for working capital ●     Share dilution risk  due to frequent discounted conversions ●     Cash position declined from $339k (Nov 2024)  to $57k (May 2025) ●     Negative cash flow from operations in Q2 2025 Governance Risks ●     Pending litigation  from Director Jeffrey Pittman seeking board oversight and appointment of a receiver (as of May 2025) ●     Concentrated control among insiders and related entities (e.g., Leonite Capital, Seminal Church, Gennex) 3. Shareholder Report Major Shareholders (as of May 31, 2025) Name Role Shares Owned Ownership % Jeffrey Pittman Director (via Seminal Church) 7,500,000 4.53% Errin Kimball Director (via Gennex Corp) 4,750,000 2.87% Nils Ollquist CEO 4,684,210 2.83% Christopher Lim CFO (via Pty Ltd) 1,050,000 0.63% Nicholas Medway Secretary 841,707 0.51% Share Structure ●     Outstanding Shares : ○     Nov 2023: 75.5M ○     May 2025: 180.9M ( +139% increase ) ●     Public Float : ~114M shares (as of May 2025) ●     Frequent equity issuance and debt conversions to Leonite Capital and AES Capital 4. Debt and Liquidity Assessment Summary (as of Q2 2025) ●     Convertible Notes (Total) : $819,199 ●     Accounts Payable : $642,000 ●     Cash : $57,000 ●     Total Liabilities : $1.79M ●     Interest Expense (Q2) : $81,000 ●     Numerous convertible promissory notes  issued to Leonite Capital and AES Capital ●     Most notes carry low conversion prices (~$0.75/share) ●     Land Usage Rights increased from $12.6M to $45M  due to transfer of JV assets to Brookmount’s full control ●     Cash flow from operations (Q2 2025) : negative ($47k) 5. Key Financial Highlights FY 2024 (Ending Nov 30) ●     Revenue : $18.45M ●     Net Income : $9.17M ●     Total Assets : $53.6M ●     Cash : $339k Q2 FY 2025 (Ending May 31) ●     Revenue : $3.75M ●     Net Income : $1.19M ●     Cash : $57k ●     Inventory : $2.13M ●     Funds Held by JV  ($30.5M) transferred to Land Usage Rights 6. Stability and Risk Opinion Risk Rating: HIGH Justification: ●     Liquidity Stress : Declining cash and negative operating cash flow signal short-term financing pressure ●     Governance Concerns : Active internal litigation; rising influence of related entities (Leonite, Gennex, Seminal) ●     Financial Leverage : Ongoing debt issuance and conversions, limited refinancing options ●     Operational Focus : Overdependence on Indonesian operations without fully commercialized North American assets ●     Share Dilution : 2.4x increase in shares within 18 months indicates pressure on shareholder value 7. Recommendations for Investors ●     Monitor future share issuances  or debt conversions , particularly involving Leonite Capital and AES Capital ●     Watch the progress of Jeffrey Pittman’s litigation ●     Track development progress of North American assets (Moosehorn and McArthur Creek) ●     Review Land Usage Rights  for valuation accuracy and reclassification implications ●     Consider dilution risks and financial sustainability before investing Email Reach us anytime. Investor Relations - ir@bmxigold.com Corporate - corporate@brookmountgold.com Phone - +1 775 234 5221 Office - 1 East Liberty Suite 600,Reno, NV 89501   https://www.brookmountgold.com/

A Bold Step into the Future of Biopharmaceutical Innovation In a world where groundbreaking medical advancements are shaping the future of healthcare, Quantum BioPharma Ltd (NASDAQ: QNTM)  stands at the forefront of a revolution in neurodegenerative and inflammatory disease treatments. With a clear mission to develop novel therapies for some of the most pressing medical conditions, Quantum BioPharma is capturing the attention of investors and healthcare professionals alike. A Visionary Company with a Groundbreaking Approach Quantum BioPharma is not just another biopharmaceutical company; it is a visionary leader in the quest to find solutions for conditions that have long been considered difficult to treat. The company’s innovative approach, spearheaded by its flagship product Lucid-MS , is set to redefine the treatment landscape for multiple sclerosis (MS) , one of the most debilitating neurodegenerative diseases in the world. MS affects millions of people globally, and current treatments focus primarily on symptom management, leaving a significant gap in curing or reversing the disease. Quantum BioPharma’s Lucid-MS , a proprietary compound, is designed to target the very heart of MS by addressing myelin degradation. In preclinical trials, Lucid-MS  has shown the potential to not only halt the progression of MS but also reverse some of the damage caused by the disease. This level of innovation has the potential to change the lives of millions who currently face a future without hope for a cure. Strong Clinical Progress and Market Potential Quantum BioPharma has already made significant strides in advancing Lucid-MS  toward commercialization. Having completed Phase-1 clinical trials successfully, the company is now positioned to move into subsequent phases of development. This progression signals confidence in the efficacy and safety of the treatment, with the prospect of reaching patients in desperate need of a novel therapeutic solution. The global market for multiple sclerosis treatments is valued at billions of dollars and continues to grow as new patient diagnoses increase. With its breakthrough therapy, Lucid-MS , Quantum BioPharma is tapping into this vast market, which promises not only to bring relief to patients but also significant revenue opportunities for the company. Diversifying into Wellness with Unbuzzd™ But Quantum BioPharma’s ambition doesn’t stop at neurodegenerative treatments. The company has also ventured into the burgeoning wellness market with its innovative product, unbuzzd™ . This unique, scientifically developed beverage is designed to support recovery after alcohol consumption, helping individuals detoxify, restore mental clarity, and improve overall well-being. With unbuzzd™ , Quantum BioPharma is addressing a market that is both diverse and rapidly expanding. The global wellness industry is valued in the trillions, and consumer interest in products that promote health and well-being is at an all-time high. Unbuzzd™ taps into a growing consumer trend seeking functional beverages that go beyond traditional soft drinks and wellness supplements, positioning Quantum BioPharma as a player in the wellness space alongside its biopharmaceutical innovations. A Talented Team Driving Change Behind every groundbreaking innovation is a team of passionate and dedicated individuals. Quantum BioPharma boasts a leadership team that combines decades of experience in biopharmaceutical development, science, and wellness. With a track record of success in launching novel products, the team at Quantum BioPharma is equipped to tackle the challenges ahead and drive the company to new heights. The Investment Opportunity: A Bright Future Ahead For investors, Quantum BioPharma offers an exciting opportunity to be part of a company poised for significant growth in multiple high-demand markets. The combination of cutting-edge biopharmaceutical development in neurodegenerative disease treatments, alongside a foray into the wellness industry, positions Quantum BioPharma as a dynamic and multifaceted company with vast potential. Quantum BioPharma's strong pipeline, proven clinical progress, and leadership team provide a solid foundation for future success. As the world continues to demand new and more effective treatments for diseases like multiple sclerosis and a greater focus on wellness solutions, Quantum BioPharma stands to capture a leading position in both the biopharma and wellness industries. For investors looking for a company with vision, innovation, and an ambitious plan for the future, Quantum BioPharma Ltd (NASDAQ: QNTM)  offers a chance to be part of something truly transformative. With significant growth potential, an expanding product portfolio, and an unwavering commitment to improving patient lives, Quantum BioPharma is a company worth watching. Invest in Quantum BioPharma  today and be part of a brighter, healthier future. About: Quantum BioPharma (NASDAQ: QNTM) is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (“ Lucid ”), Quantum BioPharma is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum BioPharma invented unbuzzd™ and spun out its OTC version to a company, Celly Nutrition Corp. (“ Celly Nutrition ”), led by industry veterans. Quantum BioPharma retains ownership of 25.71% (as of June 30, 2024) of Celly Nutrition at www.unbuzzd.com . The agreement with Celly Nutrition also includes royalty payments of 7% of sales from unbuzzd™ until payments to Quantum BioPharma total $250 million. Once $250 million is reached, the royalty drops to 3% in perpetuity. Quantum BioPharma retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses. Quantum BioPharma maintains a portfolio of strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., which represents loans secured by residential or commercial property. For more information visit www.vanderbiltreport.com .   Contact Us Sales Snap Media Group/Vanderbiltreport.com 1050 US Hwy 1 Key West, Florida 33040 Email: info@vanderbiltreport.com Web: VanderbiltReport.com

HERE IS ONE COMPANY TO KEEP YOUR EYE ON! EXPERIENCE THE POWER OF: TC BIOPHARM (NASDAQ: TCBP) CALL YOUR BROKER NOW Investing in TC BioPharm (Nasdaq: TCBP) can offer several highlights, particularly for those interested in the biotechnology sector. Here are some key points to consider: 1. Innovative Therapies    - TC BioPharm focuses on developing cell therapies, particularly for cancer treatment and other serious diseases. Their lead product, TCB-001, is designed for patients with hematologic malignancies.   2. Strong Pipeline    - The company has a robust pipeline of therapies in various stages of clinical development, which can provide multiple avenues for growth and potential revenue. 3. Experienced Management Team    - A seasoned management team with expertise in biotechnology and pharmaceuticals can enhance investor confidence in the company’s strategic direction and execution. 4. Strategic Partnerships    - Collaborations with academic institutions and other biopharmaceutical companies may provide additional resources, expertise, and validation for their products. INVEST WITH US, WHERE OPPORTUNITY MEETS GROWTH 5. Market Potential    - The market for cancer therapies is substantial and growing, driven by an increasing prevalence of cancer and a demand for more effective treatments. 6. Regulatory Progress    - Progress in regulatory approvals can be a significant catalyst for stock price appreciation. Positive results from clinical trials can lead to accelerated pathways for approval. 7. Investment in Research and Development    - A commitment to R&D can indicate potential for innovation and long-term growth, making it an attractive option for long-term investors. 8. Growing Interest in Cell Therapies    - As the field of cell therapies continues to expand, TC BioPharm is well-positioned to capitalize on this trend, which may enhance their market standing. 9. Potential for Partnerships/Acquisitions    - As the company develops its therapies, there may be opportunities for partnerships or acquisitions that could further enhance its value. 10. Investor Sentiment    - Positive news flow, successful clinical trial results, or strategic business developments can lead to favorable investor sentiment and stock performance. INVEST IN YOUR FUTURE - CALL YOUR BROKER NOW TRANSFORMING YOUR PORTFOLIO ONE TEST TRAIL AT A TIME! TAKE ACTION NOW AND CALL YOUR BROKER Unlock Your Rewards and Receive Medicus Tokens   Join Vanderbiltreport.com for all your Early Alerts S napmediagroup.net  and Vanderbiltreport.com  are owned and operated by SMG a US-based corporation. We have received compensation of up to $100,000 from KTM regarding the profiling of Citius Pharmaceuticals, Inc. (Nasdaq: TCBP)  starting on Sept 15, 2024. It is important to note that we do not own any shares in TCBP: NASDAQ .

Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP), together with its subsidiaries (including Coeptis Therapeutics, Inc. and Coeptis Pharmaceuticals, Inc., (collectively “Coeptis”), is a biopharmaceutical company developing innovative cell therapy platforms for cancer that have the potential to disrupt conventional treatment paradigms and improve patient outcomes. Coeptis’ product portfolio is highlighted by a universal, multi-antigen CAR T technology licensed from the University of Pittsburgh, and both a cell therapy technology and an in vitro diagnostic targeting CD38-related cancers (which the company is developing with VyGen-Bio and leading medical researchers at the Karolinska Institutet). Allogeneic Immune Cell Generation Platform   Ability to manufacture immune effector cells (natural killer (NK) cells, macrophages) from cord blood derived CD34+ cells Truly universal – no HLA matching required Clinically Tested: Unmodified NK cells have been investigated in two phase 1 clinical trials   Universal SNAP-CAR   Antigen agnostic chimeric antigen receptor (CAR) platform Universal SNAP-CAR construct binds to tagged antibodies directing antigen specificity and allowing for use of multiple antigens in the same indication SNAP-CAR expression in a universal immune effector cell results in the ability to use ONE off-the-shelf SNAP-CAR cell bank for use with selected tagged antibodies across multiple indications such as hematological malignancies, solid tumors, and autoimmune diseases   GEAR Platform   GEAR: “Gene-Edited Antibody Resistant” cell engineering technology Gene editing of immune effector cells to prevent fratricide when using therapeutic antibodies GEAR editing does not impact normal function of non-modified cells   Development & Clinical Collaborations   University of Pittsburgh Karolinska Institute Deverra Therapeutics Fred Hutch Cancer Center Duke Cancer Institute Novant Health

Spectral Capital Corporation (OTCQB: FCCN)  is a diversified holding company focused on acquiring and managing businesses in emerging sectors. The company seeks opportunities in industries such as technology, telecommunications, and other growth-driven markets. With a strategy centered on long-term value creation, Spectral Capital aims to maximize returns for its shareholders by leveraging its expertise and resources to support the development and expansion of its portfolio companies. By capitalizing on market trends and operational synergies, Spectral Capital strives to build a strong, sustainable business platform. HERE IS ONE COMPANY TO KEEP YOUR EYE ON! Investing in Spectral Capital, a publicly traded Deep Quantum Technology Platform Company, could offer several compelling reasons for potential investors: 1.       Cutting-Edge Technology : Spectral Capital is working at the forefront of quantum computing, a field that promises to revolutionize industries like healthcare, finance, cybersecurity, and logistics. As quantum computing moves from theoretical to practical applications, companies leading this charge stand to gain significant competitive advantages. TECHNOLOGY PLATFORMS Quantum Bridge - Noot - Monitor - Vogon - TVF - IBA 2.       Scalability Potential : By focusing on bridging the gap between quantum and classical computing, Spectral Capital is addressing a critical challenge in making quantum technology practical and scalable. Their mission to create a foundation for the next generation of technology positions them to be a key player as this transition takes place. 3.       Disruption Across Industries : As quantum computing matures, it will disrupt existing technologies. Spectral Capital’s innovations could pave the way for breakthroughs that reshape how industries operate, creating new opportunities for investors. The company's ability to integrate quantum technology with current computing systems can provide a competitive edge in the market. 4.       Strategic Market Position : Being publicly traded means that Spectral Capital is more transparent, allowing investors to assess its performance and growth potential more easily than private startups. Its positioning in a niche but rapidly expanding sector makes it an attractive choice for forward-thinking investors. INVEST WITH US, WHERE OPPORTUNITY MEETS GROWTH January 29, 2025 5.       Long-Term Growth : The development of quantum technologies is still in its early stages, meaning that long-term investments in companies like Spectral Capital have the potential for substantial returns as the market grows and matures. With ongoing investments in research and development, they’re positioned to lead this future transformation. 6.       Diverse Applications : Quantum computing could impact everything from drug discovery and materials science to artificial intelligence and cryptography. Spectral Capital’s work could have wide-reaching implications, which could mean diverse revenue streams and growth opportunities. 7.       Attractive Industry Outlook : The quantum computing market is expected to see substantial growth over the coming decades, with some estimates predicting a market worth hundreds of billions by the 2030s. Investors who enter the space early could see significant returns as the technology matures and adoption increases. Investors are Welcome INVEST IN YOUR FUTURE - CALL YOUR BROKER NOW Given these factors, investing in Spectral Capital might be a strategic move for those looking to be part of the next wave of technological innovation. The company’s ability to merge quantum and classical computing is a unique opportunity to capitalize on the evolution of technology at the highest level. DISCLAIMER Snapmediagroup.net  and Vanderbiltreport.com  are owned and operated by SMG a US based corporation. We have received compensation of up to $100,000 from KTM regarding the profiling of Spectral Capital Corp.  (OTCQB: FCCN) starting on January 12, 2025. It is important to note that we do not own any shares in FCCN: OTCQB.

Mangoceuticals, Inc. Mangoceuticals, Inc. (NASDAQ: MGRX) , also known as MangoRx, is a Dallas-based company specializing in men's health and wellness products delivered through a secure telemedicine platform. Established in 2021, the company offers treatments for erectile dysfunction (ED) under the "Mango" brand and hair loss solutions under the "Grow" brand. These products are accessible online via their website, MangoRx.com . Call your Broker now! Upgrade your investments Find out more below Invest in Mangoceuticals Inc. (NASDAQ: MGRX) Invest with MGRX where opportunity meets growth WHY MAN UP AND INVEST 1.      Expanding Market in Men’s Health & Wellness Mangoceuticals operates in the rapidly growing men’s health and wellness industry, specifically targeting the expanding market for erectile dysfunction (ED) and performance-enhancing products. With increasing consumer awareness and demand for convenient, telemedicine-driven solutions, the company is well-positioned for strong growth. 2.      Unique Branding & Direct-to-Consumer Approach The company differentiates itself with bold marketing strategies and a unique branding approach. Its flagship product, "Mango," offers an innovative take on ED medication, leveraging online sales and direct-to-consumer distribution to maximize reach and profitability. 3.      High-Growth Potential & Scalable Business Model With a digital-first strategy, Mangoceuticals can rapidly scale its business without the overhead costs of traditional pharmaceutical sales. The company is expanding its product line and exploring additional opportunities in the wellness and lifestyle enhancement markets. 4.      Strategic Marketing & Celebrity Partnerships The company actively engages in strategic marketing efforts, including influencer partnerships, sports sponsorships, and collaborations with high-profile media platforms. These initiatives enhance brand visibility and create a strong customer base. 5.      Attractive Investment in a Niche Market Unlike many competitors in the broader pharmaceutical space, Mangoceuticals focuses on a specialized niche with strong consumer demand. This targeted approach allows for high-margin sales and significant long-term revenue potential, making it an appealing investment opportunity. Invest today – Enjoy tomorrow Call your Broker Now DISCLAIMER Snapmediagroup.net  and Vanderbiltreport.com  are owned and operated by SMG a US-based corporation. We have received compensation of up to $100,000 from KTM regarding the profiling of Mangoceuticals, Inc . (Nasdaq: MGRX)  starting on February 2, 2025. It is important to note that we do not own any shares in MGRX: NASDAQ .